In the randomised phase 3 FLAURA trial involving previously untreated patients with EGFR mutant NSCLC, osimertinib attained a median PFS of 18.9 months (Soria et al., 2018), which is comparable to the median PFS (19.5 months (95% CI 18.0–20.9 months)) of our patients who received EGFR TKI only. This evidence concerns the gene EGFR and non-small cell lung carcinoma.